- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04786262
A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes
October 30, 2023 updated by: Vertex Pharmaceuticals Incorporated
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of VX-880 in Subjects Who Have Type 1 Diabetes Mellitus With Impaired Hypoglycemic Awareness and Severe Hypoglycemia
This study will evaluate the safety, tolerability and efficacy of VX-880 infusion in participants with Type 1 diabetes mellitus (T1D) and impaired awareness of hypoglycemia (IAH) and severe hypoglycemia.
Study Overview
Status
Recruiting
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
17
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Medical Information
- Phone Number: 617-341-6777
- Email: medicalinfo@vrtx.com
Study Locations
-
-
-
Edmonton, Canada
- Recruiting
- University of Alberta, Edmonton
-
Montreal, Canada
- Recruiting
- McGill University Health Centre
-
Toronto, Canada
- Recruiting
- Toronto General Hospital (TGH)
-
Vancouver, Canada
- Recruiting
- Vancouver General Hospital
-
-
-
-
-
Lille, France
- Recruiting
- CHU Lille
-
Strasbourg, France
- Recruiting
- Hopitaux Universitaires de Strasbourg
-
-
-
-
-
Dresden, Germany
- Recruiting
- Dresden Center for Islet Transplantation
-
-
-
-
-
Milan, Italy
- Recruiting
- IRCCS Ospedale San Raffaele
-
-
-
-
-
Leiden, Netherlands
- Recruiting
- Leiden University
-
-
-
-
-
Oslo, Norway
- Recruiting
- Oslo University Hospital
-
-
-
-
-
Geneve, Switzerland
- Recruiting
- Hopiteaux Universitaires de Geneve
-
-
-
-
-
Newcastle Upon Tyne, United Kingdom
- Recruiting
- The Newcastle Upon Tyne Hospitals NHS Foundation Trust
-
-
Oxford
-
Headington, Oxford, United Kingdom
- Recruiting
- Churchill Hospital
-
-
-
-
California
-
Duarte, California, United States, 91010
- Recruiting
- City of Hope
-
-
Florida
-
Miami, Florida, United States, 33136
- Recruiting
- UHealth Diabetes Research Institute
-
-
Illinois
-
Chicago, Illinois, United States, 60637
- Recruiting
- University of Chicago
-
Chicago, Illinois, United States, 60611
- Recruiting
- Northwestern Organ Transplant Center
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Recruiting
- Massachusetts General Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- Recruiting
- Hospital of the University of Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15213
- Recruiting
- University of Pittsburgh Medical Center Montefiore
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Recruiting
- VCU Medical Center, Richmond
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Recruiting
- University of Wisconsin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Key Inclusion Criteria:
- Clinical history of T1D with > 5 years of duration
- At least two episodes of documented severe hypoglycemia in the 12 months prior to enrollment
- Stable diabetic treatment
- Consistent use of continuous glucose monitor (CGM) for at least 3 months before Screening and willingness to use CGM for the duration of the study
Key Exclusion Criteria:
- Prior islet cell transplant, organ transplant, or cell therapy
Other protocol defined Inclusion/Exclusion criteria may apply
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: VX-880
|
Infused into the hepatic portal vein.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time Frame: From VX-880 infusion to end of study (up to 5 years)
|
From VX-880 infusion to end of study (up to 5 years)
|
Proportion of Participants Free of Severe Hypoglycemic Events With Either a Glycosylated Hemoglobin (HbA1c) <7.0% or a ≥ 1% Reduction in HbA1c From Baseline
Time Frame: At 1 year after VX-880 infusion
|
At 1 year after VX-880 infusion
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of Participants who are Insulin Independent
Time Frame: At 1 year after VX-880 infusion
|
At 1 year after VX-880 infusion
|
Changes in Stimulated C-peptide
Time Frame: At 1 year after VX-880 infusion
|
At 1 year after VX-880 infusion
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 29, 2021
Primary Completion (Estimated)
January 1, 2024
Study Completion (Estimated)
January 1, 2028
Study Registration Dates
First Submitted
March 3, 2021
First Submitted That Met QC Criteria
March 3, 2021
First Posted (Actual)
March 8, 2021
Study Record Updates
Last Update Posted (Actual)
October 31, 2023
Last Update Submitted That Met QC Criteria
October 30, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VX20-880-101
- 2022-002292-11 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 1
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Spiden AGDCB Research AGRecruitingType 1 Diabetes Mellitus | Type 1 Diabetes Mellitus With Hypoglycemia | Type 1 Diabetes Mellitus With HyperglycemiaSwitzerland
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
Clinical Trials on VX-880
-
NImmune BiopharmaTerminatedCrohn's DiseaseUnited States
-
Vertex Pharmaceuticals IncorporatedCompleted
-
Vertex Pharmaceuticals IncorporatedCompletedCystic FibrosisUnited States
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedActive, not recruitingCystic FibrosisUnited States, Spain, United Kingdom, Belgium, Netherlands, Denmark, Israel, New Zealand, France, Australia, Ireland, Germany, Sweden, Canada, Czechia, Switzerland, Portugal, Italy, Austria, Hungary, Norway, Poland, Greece
-
NImmune BiopharmaCompletedUlcerative ColitisUnited States, Bosnia and Herzegovina, Croatia, Poland, Ukraine
-
Vertex Pharmaceuticals IncorporatedRecruiting
-
Vertex Pharmaceuticals IncorporatedEnrolling by invitationCystic FibrosisUnited States, Australia, Germany, Sweden, Switzerland, France, Netherlands, United Kingdom
-
Vertex Pharmaceuticals IncorporatedEnrolling by invitationCystic FibrosisUnited States